PowerFleet Merger and Ocugen Gene Therapy Trial Show Promise
-
PowerFleet is transitioning to a SaaS model, focusing on recurring revenue rather than one-time hardware sales. Its impending merger with MiX Telematics could significantly boost its size and value.
-
Bitfarms continues to increase its Bitcoin mining capacity, expanding facilities and adding new miners. This drives increased profitability.
-
Ocugen's gene therapy OCU400 showed positive results in treating vision loss disorders like retinitis pigmentosa and Leber congenital amaurosis.
-
OCU400 demonstrated efficacy across diverse genetic mutations, suggesting it could treat multiple mutations with a single product.
-
83% of OCU400 clinical trial participants exhibited stable or improved vision across various metrics like visual acuity and mobility testing.